<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02577354</url>
  </required_header>
  <id_info>
    <org_study_id>950057</org_study_id>
    <nct_id>NCT02577354</nct_id>
  </id_info>
  <brief_title>ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain</brief_title>
  <acronym>ReActiv8-B</acronym>
  <official_title>ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain (ReActiv8-B)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mainstay Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mainstay Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and efficacy of ReActiv8 for the&#xD;
      treatment of adults with Chronic Low Back Pain when used in conjunction with medical&#xD;
      management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate of Low Back Pain With No Increase in Pain Medications</measure>
    <time_frame>120 Days</time_frame>
    <description>Comparison of responder rates for low back pain VAS between Treatment and Control groups.&#xD;
The Primary Efficacy Endpoint is a comparison of responder rates between Treatment and Control groups, where a &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
Any increase in dosage of a pain medication or any new pain medication taken for any reason counts as an increase in medications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in Low Back Pain VAS</measure>
    <time_frame>120 Days</time_frame>
    <description>Comparison of change in LBP VAS (120 days from baseline) between the Treatment and Control groups. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Proportion of Responders Analysis (CPRA) for the Primary Endpoint to Compare Participants Responses Over a Full Range of Response Levels</measure>
    <time_frame>120 Days</time_frame>
    <description>The CPRA, which was prespecified in the clinical protocol and statistical analysis plan prior to the start of the trial, was performed using the same data as used for the primary endpoint analysis and was included as part of the primary endpoint analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Device and/or Procedure Related Adverse Event Rate</measure>
    <time_frame>120 Days</time_frame>
    <description>The primary safety assessment is of serious device and/or procedure related adverse events in all participants at 120 days.&#xD;
The 8 events reported below are 6 implant site pocket infections, 1 intra-operative upper airway obstruction, and 1 non-radicular, focal numbness on the surface of the thigh.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index (ODI)</measure>
    <time_frame>120 Days</time_frame>
    <description>Comparison of change in ODI (120 days from baseline) between Treatment and Control groups. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life Score on Five Dimensions (EQ-5D)</measure>
    <time_frame>120 Days</time_frame>
    <description>Comparison of change in EQ-5D (120 days from baseline) between Treatment and Control groups. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Pain Relief (PPR)</measure>
    <time_frame>120 Days</time_frame>
    <description>PPR is a patient-reported percent of pain relief at 120 days compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Impression of Change (SGIC)</measure>
    <time_frame>120 Days</time_frame>
    <description>A questionnaire completed with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Back Pain (VAS ≤2.5 cm)</measure>
    <time_frame>120 Days</time_frame>
    <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP VAS Responder Rate at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>A &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in LBP VAS at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Change in LBP VAS at 1 year compared to baseline. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, one for each symptom extreme for Low Back Pain. Zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index (ODI) at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Change in ODI at 1 year compared to baseline. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in European Quality of Life Score on Five Dimensions (EQ-5D) at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Change in EQ-5D at 1 year compared to baseline. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Pain Relief at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>PPR is a patient-reported percent of pain relief compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Impression of Change (SGIC) at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>A questionnaire with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Back Pain at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Supplementary Analysis of Primary Endpoint: Responder Rate of Low Back Pain With No Increase in Low Back Pain Medications</measure>
    <time_frame>120 Days</time_frame>
    <description>This pre-specified analysis of the primary endpoint examines the impact of rescue medications taken for acute pain conditions for reasons other than low back pain, by excluding those participants from the analysis who took rescue medications for reasons other than low back pain.&#xD;
Nine participants in both groups increased pain medications. In the control group, all nine participants increased pain medications due to low back pain. In the treatment group, three of the nine participants increased pain medications due to low back pain, while six of the nine participants increased pain medications for reasons other than low back pain. Since any increase in pain medications automatically considers a participant a non-responder, these six participants are removed from this analysis to eliminate the confounding factor of increases in pain medications for reasons other than low back pain.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>120 Days</time_frame>
    <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Satisfaction at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the outcome of the treatment.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>120 Days</time_frame>
    <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression of Change at One Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Opioid Use for Treatment of Low Back Pain at One-Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Any increase or decrease of dosage or frequency of an opioid taken for the treatment of low back pain was considered a change.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)</intervention_name>
    <description>ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReActiv8 Implantable Stimulation System (Low Stimulation)</intervention_name>
    <description>ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥22 years, ≤75 years&#xD;
&#xD;
          2. Chronic Low Back Pain that has persisted &gt;90 days prior to the baseline visit.&#xD;
&#xD;
          3. Continuing low back pain despite &gt;90 days of medical management.&#xD;
&#xD;
          4. Qualifying pain score.&#xD;
&#xD;
          5. Qualifying disability score.&#xD;
&#xD;
          6. Evidence of lumbar multifidus muscle dysfunction.&#xD;
&#xD;
          7. Be willing and capable of giving Informed Consent.&#xD;
&#xD;
          8. Ability to comply with the instructions for use and to operate ReActiv8, and to comply&#xD;
             with this Clinical Investigation Plan.&#xD;
&#xD;
          9. Suitable for ReActiv8 surgery as determined by the implanting physician prior to&#xD;
             inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt; 35&#xD;
&#xD;
          2. Back Pain characteristics:&#xD;
&#xD;
               1. Any surgical correction procedure for scoliosis at any time, or a current&#xD;
                  clinical diagnosis of scoliosis.&#xD;
&#xD;
               2. Lumbar spine stenosis, as defined by an anterior-posterior diameter of the spinal&#xD;
                  canal of &lt;10mm in subjects with lower extremity pain.&#xD;
&#xD;
               3. Neurological deficit possibly associated with the back pain (e.g. foot drop).&#xD;
&#xD;
               4. Back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or&#xD;
                  infection (e.g.: post herpetic neuralgia).&#xD;
&#xD;
               5. Back pain due to inflammation or damage to the spinal cord or adjacent structures&#xD;
                  (e.g. arachnoiditis or syringomyelia).&#xD;
&#xD;
               6. Pathology seen on MRI that is clearly identified and is likely the cause of the&#xD;
                  CLBP that is amenable to surgery.&#xD;
&#xD;
               7. Back pain due to vascular causes such as aortic aneurysm and dissection.&#xD;
&#xD;
          3. Any current indication for back surgery according to local institutional guidelines,&#xD;
             or has indication for back surgery but cannot undergo surgery for other reasons.&#xD;
&#xD;
          4. Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain)&#xD;
             below the knee.&#xD;
&#xD;
          5. Source of pain is the sacroiliac joint as determined by the Investigator.&#xD;
&#xD;
          6. Drug use.&#xD;
&#xD;
          7. Surgical and other procedures exclusions.&#xD;
&#xD;
          8. Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or&#xD;
             lumbar annular tear with disc protrusion that is amenable to surgery.&#xD;
&#xD;
          9. Planned surgery.&#xD;
&#xD;
         10. Co-morbid chronic pain conditions.&#xD;
&#xD;
         11. Other clinical conditions.&#xD;
&#xD;
         12. Psycho-social exclusions.&#xD;
&#xD;
         13. Protocol compliance exclusions.&#xD;
&#xD;
         14. General exclusions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Gilligan, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Spine Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoIndy</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Health</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Stokes VA Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Trials</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Orthopaedic Specialists</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pain Relief</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Research Services</name>
      <address>
        <city>Broadmeadow</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast Clinical Research</name>
      <address>
        <city>Noosa Heads</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pain Medicine of South Australia</name>
      <address>
        <city>Welland</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Clinical Research</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seacroft Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02577354/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02577354/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
        </group>
        <group group_id="P2">
          <title>Control/Crossover</title>
          <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>120 Day Primary Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
        </group>
        <group group_id="B2">
          <title>Control/Crossover</title>
          <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="10"/>
                    <measurement group_id="B2" value="48" spread="9"/>
                    <measurement group_id="B3" value="47" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="4"/>
                    <measurement group_id="B2" value="28" spread="4"/>
                    <measurement group_id="B3" value="28" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Duration (years from onset)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.4" spread="10.8"/>
                    <measurement group_id="B2" value="13.9" spread="10.4"/>
                    <measurement group_id="B3" value="14.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of Days with Low Back Pain</title>
          <description>Participant report of percent of days in the past 12 months with low back pain.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97" spread="8"/>
                    <measurement group_id="B2" value="97" spread="8"/>
                    <measurement group_id="B3" value="97" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evidence of Leg Pain</title>
          <description>Participant report of current leg pain.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior Physical Therapy Sessions</title>
          <units>sessions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="39"/>
                    <measurement group_id="B2" value="32" spread="63"/>
                    <measurement group_id="B3" value="31" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Rhizotomy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Injection Procedures</title>
          <description>Injection procedures refers to epidural procedures (e.g., spinal block)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS for Low Back Pain</title>
          <description>The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread=".7"/>
                    <measurement group_id="B2" value="7.2" spread=".7"/>
                    <measurement group_id="B3" value="7.3" spread=".7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oswestry Disability Index</title>
          <description>ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="10"/>
                    <measurement group_id="B2" value="38" spread="10"/>
                    <measurement group_id="B3" value="39" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D-5L Index Score</title>
          <description>The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.572" spread="0.182"/>
                    <measurement group_id="B2" value="0.598" spread="0.165"/>
                    <measurement group_id="B3" value="0.585" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Back Pain Medications of Any Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Opioid Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responder Rate of Low Back Pain With No Increase in Pain Medications</title>
        <description>Comparison of responder rates for low back pain VAS between Treatment and Control groups.&#xD;
The Primary Efficacy Endpoint is a comparison of responder rates between Treatment and Control groups, where a &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
Any increase in dosage of a pain medication or any new pain medication taken for any reason counts as an increase in medications.</description>
        <time_frame>120 Days</time_frame>
        <population>100 treatment group participants and 101 control group participants returned for the 120 day visit. Results for the 3 participants lost to follow-up were included using multiple imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient-appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate of Low Back Pain With No Increase in Pain Medications</title>
          <description>Comparison of responder rates for low back pain VAS between Treatment and Control groups.&#xD;
The Primary Efficacy Endpoint is a comparison of responder rates between Treatment and Control groups, where a &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
Any increase in dosage of a pain medication or any new pain medication taken for any reason counts as an increase in medications.</description>
          <population>100 treatment group participants and 101 control group participants returned for the 120 day visit. Results for the 3 participants lost to follow-up were included using multiple imputation.</population>
          <units>percentage of responsers</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.138</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05</p_value_desc>
            <method>Wald asymptotic test of proportions</method>
            <method_desc>Cui p-value adjustment for sample size re-estimation at interim analysis; Multiple imputation utilized for 3 participants lost to follow-up.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Low Back Pain VAS</title>
        <description>Comparison of change in LBP VAS (120 days from baseline) between the Treatment and Control groups. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
        <time_frame>120 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Low Back Pain VAS</title>
          <description>Comparison of change in LBP VAS (120 days from baseline) between the Treatment and Control groups. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, where zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="2.7"/>
                    <measurement group_id="O2" value="-2.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Proportion of Responders Analysis (CPRA) for the Primary Endpoint to Compare Participants Responses Over a Full Range of Response Levels</title>
        <description>The CPRA, which was prespecified in the clinical protocol and statistical analysis plan prior to the start of the trial, was performed using the same data as used for the primary endpoint analysis and was included as part of the primary endpoint analysis</description>
        <time_frame>120 Days</time_frame>
        <population>3 participants lost to follow-up included using multiple imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Proportion of Responders Analysis (CPRA) for the Primary Endpoint to Compare Participants Responses Over a Full Range of Response Levels</title>
          <description>The CPRA, which was prespecified in the clinical protocol and statistical analysis plan prior to the start of the trial, was performed using the same data as used for the primary endpoint analysis and was included as part of the primary endpoint analysis</description>
          <population>3 participants lost to follow-up included using multiple imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;0% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0"/>
                    <measurement group_id="O2" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0"/>
                    <measurement group_id="O2" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;30% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;60% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0"/>
                    <measurement group_id="O2" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;80% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;90% Reduction in Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0499</p_value>
            <p_value_desc>The threshold for significance was p=0.05.</p_value_desc>
            <method>Friedman's regression analysis</method>
            <method_desc>Multiple Imputation utilized for 3 participants lost to follow-up.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Device and/or Procedure Related Adverse Event Rate</title>
        <description>The primary safety assessment is of serious device and/or procedure related adverse events in all participants at 120 days.&#xD;
The 8 events reported below are 6 implant site pocket infections, 1 intra-operative upper airway obstruction, and 1 non-radicular, focal numbness on the surface of the thigh.</description>
        <time_frame>120 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Device and/or Procedure Related Adverse Event Rate</title>
          <description>The primary safety assessment is of serious device and/or procedure related adverse events in all participants at 120 days.&#xD;
The 8 events reported below are 6 implant site pocket infections, 1 intra-operative upper airway obstruction, and 1 non-radicular, focal numbness on the surface of the thigh.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oswestry Disability Index (ODI)</title>
        <description>Comparison of change in ODI (120 days from baseline) between Treatment and Control groups. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oswestry Disability Index (ODI)</title>
          <description>Comparison of change in ODI (120 days from baseline) between Treatment and Control groups. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="15.1"/>
                    <measurement group_id="O2" value="-12.2" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in European Quality of Life Score on Five Dimensions (EQ-5D)</title>
        <description>Comparison of change in EQ-5D (120 days from baseline) between Treatment and Control groups. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up. An additional patient in the Control group did not complete the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in European Quality of Life Score on Five Dimensions (EQ-5D)</title>
          <description>Comparison of change in EQ-5D (120 days from baseline) between Treatment and Control groups. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up. An additional patient in the Control group did not complete the questionnaire.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.199"/>
                    <measurement group_id="O2" value="0.115" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Pain Relief (PPR)</title>
        <description>PPR is a patient-reported percent of pain relief at 120 days compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Pain Relief (PPR)</title>
          <description>PPR is a patient-reported percent of pain relief at 120 days compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="32"/>
                    <measurement group_id="O2" value="35" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance was 0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Impression of Change (SGIC)</title>
        <description>A questionnaire completed with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Impression of Change (SGIC)</title>
          <description>A questionnaire completed with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Back Pain (VAS ≤2.5 cm)</title>
        <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Back Pain (VAS ≤2.5 cm)</title>
          <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.335</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LBP VAS Responder Rate at One Year</title>
        <description>A &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>LBP VAS Responder Rate at One Year</title>
          <description>A &quot;responder&quot; is a participant with ≥30% reduction from baseline in average low back pain VAS, without any increase from baseline in pain medications and/or muscle relaxants for any reason including non low back pain reasons.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in LBP VAS at One Year</title>
        <description>Change in LBP VAS at 1 year compared to baseline. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, one for each symptom extreme for Low Back Pain. Zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient-appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in LBP VAS at One Year</title>
          <description>Change in LBP VAS at 1 year compared to baseline. The instrument used for evaluating pain is the continuous Visual Analog Scale (VAS) comprised of a horizontal line 10 cm in length, anchored by 2 verbal descriptors, one for each symptom extreme for Low Back Pain. Zero indicates no pain and 10 indicates worst imaginable pain. The value reported is a 7-day average low back pain.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
          <population>Participants with data at one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.7"/>
                    <measurement group_id="O2" value="-4.3" spread="2.5"/>
                    <measurement group_id="O3" value="-4.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oswestry Disability Index (ODI) at One Year</title>
        <description>Change in ODI at 1 year compared to baseline. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oswestry Disability Index (ODI) at One Year</title>
          <description>Change in ODI at 1 year compared to baseline. ODI is reported as a score from 0 to 100%, where 0%-20% indicates minimal disability, 21%-40% indicates moderate disability, 41%-60% indicates severe disability, 61%-80% indicates crippled, and 81%-100% indicates bedbound or an exaggeration of symptoms.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a lower score (negative value) indicates improvement.</description>
          <population>Participants with data at one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.1" spread="17.2"/>
                    <measurement group_id="O2" value="-19.8" spread="14.5"/>
                    <measurement group_id="O3" value="-19.9" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in European Quality of Life Score on Five Dimensions (EQ-5D) at One Year</title>
        <description>Change in EQ-5D at 1 year compared to baseline. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in European Quality of Life Score on Five Dimensions (EQ-5D) at One Year</title>
          <description>Change in EQ-5D at 1 year compared to baseline. The EQ-5D Index is scored on a scale of -0.594 to 1.00, with a score of 1.00 indicating full health.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.&#xD;
A change to a higher score (positive value) indicates improvement.</description>
          <population>Participants with data at one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.210" spread="0.235"/>
                    <measurement group_id="O2" value="0.187" spread="0.177"/>
                    <measurement group_id="O3" value="0.198" spread="0.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Pain Relief at One Year</title>
        <description>PPR is a patient-reported percent of pain relief compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Pain Relief at One Year</title>
          <description>PPR is a patient-reported percent of pain relief compared to the pain at baseline, where 0% indicates no pain relief compared to baseline, and 100% indicates complete pain relief compared to baseline.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" spread="33"/>
                    <measurement group_id="O2" value="66" spread="33"/>
                    <measurement group_id="O3" value="66" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Impression of Change (SGIC) at One Year</title>
        <description>A questionnaire with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Impression of Change (SGIC) at One Year</title>
          <description>A questionnaire with the following item: Since I enrolled in the study, my overall status is 1) Very much improved, 2) Much improved, 3) Minimally improved, 4) No change, 5) Minimally worse, 6) Much worse, 7) Very much worse&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Much Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A Little Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A Little Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Back Pain at One Year</title>
        <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Back Pain at One Year</title>
          <description>Resolution of back pain (remitter rate) was defined as a participant with 7-day average low back pain VAS ≤2.5 cm on the 10 cm VAS.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Supplementary Analysis of Primary Endpoint: Responder Rate of Low Back Pain With No Increase in Low Back Pain Medications</title>
        <description>This pre-specified analysis of the primary endpoint examines the impact of rescue medications taken for acute pain conditions for reasons other than low back pain, by excluding those participants from the analysis who took rescue medications for reasons other than low back pain.&#xD;
Nine participants in both groups increased pain medications. In the control group, all nine participants increased pain medications due to low back pain. In the treatment group, three of the nine participants increased pain medications due to low back pain, while six of the nine participants increased pain medications for reasons other than low back pain. Since any increase in pain medications automatically considers a participant a non-responder, these six participants are removed from this analysis to eliminate the confounding factor of increases in pain medications for reasons other than low back pain.</description>
        <time_frame>120 Days</time_frame>
        <population>Responder rate (≥30% reduction in low back pain VAS and no increase in pain medications). Six participants with increases in pain medications for reasons other than low back pain are removed from this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient-appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Supplementary Analysis of Primary Endpoint: Responder Rate of Low Back Pain With No Increase in Low Back Pain Medications</title>
          <description>This pre-specified analysis of the primary endpoint examines the impact of rescue medications taken for acute pain conditions for reasons other than low back pain, by excluding those participants from the analysis who took rescue medications for reasons other than low back pain.&#xD;
Nine participants in both groups increased pain medications. In the control group, all nine participants increased pain medications due to low back pain. In the treatment group, three of the nine participants increased pain medications due to low back pain, while six of the nine participants increased pain medications for reasons other than low back pain. Since any increase in pain medications automatically considers a participant a non-responder, these six participants are removed from this analysis to eliminate the confounding factor of increases in pain medications for reasons other than low back pain.</description>
          <population>Responder rate (≥30% reduction in low back pain VAS and no increase in pain medications). Six participants with increases in pain medications for reasons other than low back pain are removed from this analysis.</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6"/>
                    <measurement group_id="O2" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>The threshold for statistical significance was p=0.05.</p_value_desc>
            <method>Wald asymptotic test of proportions</method>
            <method_desc>Multiple imputation used for three participants lost to follow-up.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment Satisfaction</title>
        <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the treatment.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction</title>
          <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the treatment.</description>
          <population>Completers Analysis. Three participants (2 Treatment, 1 Control) were lost to follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Definitely Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maybe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definitely Not</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for &quot;Satisfied with Treatment&quot;. Threshold for statistical significance was p=0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment Satisfaction at One Year</title>
        <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the outcome of the treatment.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After the 120-day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Satisfaction at One Year</title>
          <description>The Treatment Satisfaction Questionnaire asking the participant if they are satisfied with the outcome of the treatment.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Definitely Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maybe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definitely Not</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Global Impression of Change</title>
        <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.</description>
        <time_frame>120 Days</time_frame>
        <population>Completers Analysis. Three participants were lost to follow-up (2 Treatment, 1 Control). The questionnaire was not completed for an additional participant in the Control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change</title>
          <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.</description>
          <population>Completers Analysis. Three participants were lost to follow-up (2 Treatment, 1 Control). The questionnaire was not completed for an additional participant in the Control group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Much Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slightly Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About the Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slightly Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance was p=0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Global Impression of Change at One Year</title>
        <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
          </group>
          <group group_id="O2">
            <title>Control/Crossover</title>
            <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
          </group>
          <group group_id="O3">
            <title>All (Treatment and Control/Crossover Combined)</title>
            <description>At the 1 Year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriated therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control/Crossover Group). This column provides the results for all participants in one group.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression of Change at One Year</title>
          <description>Clinical Global Impression consists of the following question completed by the Investigator prior to unblinding: In your opinion as a clinician, compared to the patient's situation at baseline, would you say the patient is: 1) Much better, 2) Slightly better, 3) About the same, 4) Slightly worse, 5) Much worse.&#xD;
After the 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level. At the one-year time point, participants in the Control/Crossover group have received 8 months of patient-appropriate therapy.</description>
          <population>Participants with data at one year.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Much Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slightly Better</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About the Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slightly Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much Worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Opioid Use for Treatment of Low Back Pain at One-Year</title>
        <description>Any increase or decrease of dosage or frequency of an opioid taken for the treatment of low back pain was considered a change.</description>
        <time_frame>1 Year</time_frame>
        <population>Participants with data at one year who were on opioids at baseline. Since changes in opioids are evaluated only at 1 year (and not compared between groups at 120 days), and all participants are receiving therapy at the 1 year time point, there is no between group comparison. Therefore, the groups are combined for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Combined</title>
            <description>At the 1-year visit, all participants are receiving patient-appropriate therapy (1 year of patient-appropriate therapy for the Treatment Group, and 8 months of patient-appropriate therapy for the Control Group).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Opioid Use for Treatment of Low Back Pain at One-Year</title>
          <description>Any increase or decrease of dosage or frequency of an opioid taken for the treatment of low back pain was considered a change.</description>
          <population>Participants with data at one year who were on opioids at baseline. Since changes in opioids are evaluated only at 1 year (and not compared between groups at 120 days), and all participants are receiving therapy at the 1 year time point, there is no between group comparison. Therefore, the groups are combined for this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Discontinued or Decreased</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increased or Added</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events were collected through the 120 day primary endpoint and through one year per the Investigational Device Exemption (IDE). The FDA required a minimum of 150 participants through one year prior to Premarket Approval (PMA) application. These results are adverse events (related and unrelated) reported through the one year visit.</time_frame>
      <desc>All adverse events were adjudicated by a Clinical Events Committee comprised of independent physicians. The committee adjudicated the type of event, severity of event, and relatedness to the system or procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment -- Blinded Phase (0-120 Days)</title>
          <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
        </group>
        <group group_id="E2">
          <title>Control -- Blinded Phase (0-120 Days)</title>
          <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
        </group>
        <group group_id="E3">
          <title>Treatment -- Open Label Phase (121-365 Days)</title>
          <description>ReActiv8 Implantable Stimulation System (patient appropriate stimulation): ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level and participants instructed to deliver stimulation in two 30-minute sessions per day.</description>
        </group>
        <group group_id="E4">
          <title>Crossover -- Open Label Phase (121-365 Days)</title>
          <description>ReActiv8 Implantable Stimulation System (low stimulation): ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.&#xD;
After 120 day visit, participants crossed over to have their device programmed to deliver stimulation at a patient-appropriate level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallstones</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Implant site pocket infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness in Leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-operative airway obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA(19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Implant site pocket pain/discomfort</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain Aggravated</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pain in Hip</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device overstimulation of tissue</sub_title>
                <description>Discomfort associated with stimulation, often related to the titration of therapy and typically resolved with reprogramming.</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Dichotomization of primary endpoint reduced statistical power by losing information on exact response magnitude. This limitation is addressed by the cumulative proportion of responders analysis of the primary endpoint data (Outcome Measure #3).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President Clinical Affairs</name_or_title>
      <organization>Mainstay Medical</organization>
      <phone>7637727637</phone>
      <email>diane.burnside@mainstay-medical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

